Inventor · disambiguated record
Charlotte Mary Griffiths-Jones
Also filed as: GRIFFITHS-JONES CHARLOTTE MARY
23 granted patents·12 pending applications·131 citations·filing 2007–2024
95Inventor score
Files withASTEX THERAPEUTICS LTD15GLAXOSMITHKLINE IP DEV LTD8OTSUKA PHARMA CO LTD4SAXTY GORDON4BERDINI VALERIO3
Top patents by PatentIndex Score
35 records- 0193US11225476B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2020·Granted Jan 18, 2022·3 cites·13 claims
- 0292US11866428B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2020·Granted Jan 9, 2024·2 cites·21 claims
- 0392US11001575B1Benzolactam compounds as protein kinase inhibitorsOTSUKA PHARMA CO LTD·Filed 2019·Granted May 11, 2021·4 cites·26 claims
- 0492US8895745B2Bicyclic heterocyclic compounds as FGFR inhibitorsBERDINI VALERIO·Filed 2007·Granted Nov 25, 2014·33 cites·20 claims
- 0591US10457669B2Benzolactam compounds as protein kinase inhibitorsOTSUKA PHARMA CO LTD·Filed 2016·Granted Oct 29, 2019·5 cites·25 claims
- 0691US9783538B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2014·Granted Oct 10, 2017·12 cites·53 claims
- 0790US11643410B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2021·Granted May 9, 2023·1 cites·22 claims
- 0890US9676768B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2015·Granted Jun 13, 2017·8 cites·16 claims
- 0990US8071614B2Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitorsSAXTY GORDON·Filed 2008·Granted Dec 6, 2011·16 cites·12 claims
- 1089US2025296930A1Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 1187US10618895B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2017·Granted Apr 14, 2020·4 cites·33 claims
- 1287US9018214B2Bicyclic heterocycle compounds and their uses in therapyWOOLFORD ALISON JO-ANNE·Filed 2012·Granted Apr 28, 2015·13 cites·21 claims
- 1387US8076354B2Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitorsSAXTY GORDON·Filed 2008·Granted Dec 13, 2011·9 cites·13 claims
- 1485US2024199607A1Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 1584US12202828B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2022·Granted Jan 21, 2025·0 cites·48 claims
- 1684US8859582B2Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitorsSAXTY GORDON·Filed 2011·Granted Oct 14, 2014·7 cites·20 claims
- 1783US8513276B2Imidazo[1,2-a]pyridine compounds for use in treating cancerBERDINI VALERIO·Filed 2007·Granted Aug 20, 2013·8 cites·16 claims
- 1882US2024368136A1Benzolactam compounds as protein kinase inhibitorsOTSUKA PHARMA CO LTD·Filed 2023·Application pending·0 cites
- 1981US2025084077A1Ether linked triazoles as nrf2 activatorsASTEX THERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 2079US11603367B2Isoindolinone inhibitors of the MDM2-P53 interaction and process for making themASTEX THERAPEUTICS LTD·Filed 2018·Granted Mar 14, 2023·2 cites·12 claims
- 2177US10364256B2Biaryl pyrazoles as NRF2 regulatorsGLAXOSMITHKLINE IP DEV LTD·Filed 2016·Granted Jul 30, 2019·2 cites·15 claims
- 2273US8796244B2Imidazopyridine derivatives as inhibitors of receptor tyrosine kinasesBERDINI VALERIO·Filed 2009·Granted Aug 5, 2014·2 cites·21 claims
- 2372US11939321B2Benzolactam compounds as protein kinase inhibitorsOTSUKA PHARMA CO LTD·Filed 2021·Granted Mar 26, 2024·0 cites·28 claims
- 2470US2025074900A1Isoindolinone inhibitors of the mdm2-p53 interaction and process for making themASTEX THERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 2569US12091409B2Ether linked triazoles as NRF2 activatorsASTEX THERAPEUTICS LTD·Filed 2021·Granted Sep 17, 2024·0 cites·9 claims
- 2669US2023047296A1Nrf2 REGULATORSGLAXOSMITHKLINE IP DEV LTD·Filed 2021·Application pending·0 cites
- 2767US2019375748A1Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 2864US11059816B2Ether linked triazoles as NRF2 activatorsGLAXOSMITHKLINE IP DEV LTD·Filed 2017·Granted Jul 13, 2021·0 cites·4 claims
- 2961US2017334907A1Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2017·Application pending·0 cites
- 3058US2020079759A1Nrf2 REGULATORSGLAXOSMITHKLINE IP DEV LTD·Filed 2019·Application pending·0 cites
- 3150US2019002454A1NRF2 RegulatorsGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Application pending·0 cites
- 3249US8859583B2Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitorsSAXTY GORDON·Filed 2011·Granted Oct 14, 2014·0 cites·20 claims
- 3341US2020071310A1N-aryl pyrazoles as nrf2 regulatorsGLAXOSMITHKLINE IP DEV LTD·Filed 2017·Application pending·0 cites
- 3437US10351530B2Arylcyclohexyl pyrazoles as NRF2 regulatorsGLAXOSMITHKLINE IP DEV LTD·Filed 2016·Granted Jul 16, 2019·0 cites·8 claims
- 3537US2018179167A1Nrf2 REGULATORSGLAXOSMITHKLINE IP DEV LTD·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →